NOT-AI-26-009: Notice of Early Expiration of PAR-25-316 "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)"

Notice of Early Expiration of PAR-25-316 "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)"

Notice Number:

NOT-AI-26-009

Key Dates

Release Date:

February 18, 2026

Related Announcements

December 18, 2024- Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed). See NOFO PAR-25-316.

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this Notice is to inform the extramural community that PAR-25-316 “Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)” will be expired effective immediately. No further applications will be accepted for this notice of funding opportunity (NOFO).

Inquiries

Please direct all inquiries to:

National Institute of Allergy and Infectious Diseases (NIAID)

[email protected]